Neurogenic lower urinary tract dysfunction: evaluation and management

被引:0
作者
Katarina Ivana Tudor
Ryuji Sakakibara
Jalesh N. Panicker
机构
[1] University Hospital Center Zagreb,Department of Neurology
[2] Toho University,Neurology Division, Department of Internal Medicine, Sakura Medical Center
[3] University College London (UCL),Department of Uro
来源
Journal of Neurology | 2016年 / 263卷
关键词
Overactive bladder; OAB; Neurogenic bladder; Incontinence; Urodynamics; Fowler’s syndrome; Antimuscarinics; Tibial nerve stimulation;
D O I
暂无
中图分类号
学科分类号
摘要
The lower urinary tract (LUT) in health is regulated by coordinated multi-level neurological inputs which require an intact central and peripheral nervous system. Lower urinary tract dysfunction is, therefore, a common sequelae of neurological disease and the patterns of bladder storage and voiding dysfunction depend upon the level of neurological lesion. Evaluation includes history taking, bladder diary, urological examination when relevant, ultrasonography and urodynamic testing when indicated. Antimuscarinic agents are the first line treatment for patients with storage dysfunction. Alternative treatments include intradetrusor injection of onabotulinumtoxinA, which has been shown to be of benefit in patients with neurogenic detrusor overactivity (NDO), and neuromodulation. Intermittent catheterization remains the option of choice in patients with significant voiding dysfunction resulting in high post-void residual volumes.
引用
收藏
页码:2555 / 2564
页数:9
相关论文
共 400 条
[91]  
Harris C(2011)Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial Eur Urol 60 742-333
[92]  
Harrison SC(2012)Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity J Urol 187 2131-1714
[93]  
Kirby M(2015)Summary of European Association of Urology (EAU) guidelines on neuro-urology Eur Urol 69 324-undefined
[94]  
Chancellor MB(2008)Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 70 1707-undefined
[95]  
Anderson RU(undefined)undefined undefined undefined undefined-undefined
[96]  
Boone TB(undefined)undefined undefined undefined undefined-undefined
[97]  
De Ridder D(undefined)undefined undefined undefined undefined-undefined
[98]  
Van Der Aa F(undefined)undefined undefined undefined undefined-undefined
[99]  
Debruyne J(undefined)undefined undefined undefined undefined-undefined
[100]  
D’Hooghe MB(undefined)undefined undefined undefined undefined-undefined